错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Senescent cancer-associated fibroblasts in pancreatic adenocarcinoma restrict CD8+ T cell activation and limit responsiveness to immunotherapy in mice

  • Benjamin Assouline,
  • Rachel Kahn,
  • Lutfi Hodali,
  • Reba Condiotti,
  • Yarden Engel,
  • Ela Elyada,
  • Tzlil Mordechai-Heyn,
  • Jason R. Pitarresi,
  • Dikla Atias,
  • Eliana Steinberg,
  • Tirza Bidany-Mizrahi,
  • Esther Forkosh,
  • Lior H. Katz,
  • Ofra Benny,
  • Talia Golan,
  • Matan Hofree,
  • Sheila A. Stewart,
  • Karine A. Atlan,
  • Gideon Zamir,
  • Ben Z. Stanger,
  • Michael Berger,
  • Ittai Ben-Porath

摘要

Senescent cells within tumors and their stroma exert complex pro- and anti-tumorigenic functions. However, the identities and traits of these cells, and the potential for improving cancer therapy through their targeting, remain poorly characterized. Here, we identify a senescent subset within previously-defined cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinomas (PDAC) and in premalignant lesions in mice and humans. Senescent CAFs isolated from mouse and humans expressed elevated levels of immune-regulatory genes. Depletion of senescent CAFs, either genetically or using the Bcl-2 inhibitor ABT-199 (venetoclax), increased the proportion of activated CD8+ T cells in mouse pancreatic carcinomas, whereas induction of CAF senescence had the opposite effect. Combining ABT-199 with an immune checkpoint therapy regimen significantly reduced mouse tumor burden. These results indicate that senescent CAFs in PDAC stroma limit the numbers of activated cytotoxic CD8+ T cells, and suggest that their targeted elimination through senolytic treatment may enhance immunotherapy.